A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

555

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Follicular Lymphoma
Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions

DRUG: Tazemetostat
DRUG: Tazemetostat
DRUG: Placebo oral tablet
COMBINATION_PRODUCT: Lenalidomide
COMBINATION_PRODUCT: Rituximab

Sponsor

Epizyme, Inc.